

LOGFRAME MATRIX OF THE EMCDDA–IPA6 PROJECT

The logframe matrix should evolve during the project lifetime: new lines can be added for listing new activities as well as new columns for intermediary targets (milestones) when it is relevant and values will be regularly updated in the column foreseen for reporting purpose (see “current value”).

	Results chain	Indicators	Baseline (2017)	Current value Reference date	Targets (June 2019)	Sources and means of verification	Assumptions
Overall objective: Impact	To ensure that IPA II beneficiaries are able to participate in the activities of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and its Reitox network, upon accession.	Progress achieved by the IPA II beneficiaries towards their full preparation for the participation in the work of the EMCDDA	IPA BC are not yet fully prepared to participate in the work of the EMCDDA		40% of the recommendations listed in the 2016 roadmaps are addressed by the BC national authorities	Roadmaps September 2016 Roadmaps May 2019	BC willingness to engage in activities with the EMCDDA, incl. taking into account recommendations in roadmaps
Specific objective(s): Outcome(s)	To support the approximation to and adoption of the EU acquis in the IPA II beneficiaries in the area of Rule of Law and in particular in the drug information field.	Degree of compliance with the acquis namely: - A) existing National Drug Observatory (NDO) - B) existing data collection and reporting capacity fully comparable to the EU - C). existing national Early Warning System (EWS) in the Beneficiary Countries (BC)	A) 3 NDOs out of 6 foreseen; B) reporting data collection system not fully comparable to the EU C) 1 partially functioning national EWS		A) 5 out of 6 NDOs B) reporting data collection system closer to EU standards C) 3 to 4 countries participating in the EWS	Roadmaps September 2016 Roadmaps May 2019 NEWS profiles	NDO existing in their national legislation and operational National support / willingness to engage in additional data collection exercises

	Results chain	Indicators	Baseline (2017)	Current value Reference date	Targets (June 2019)	Sources and means of verification	Assumptions
Outputs	Op 1.1: strengthened coordination body at national level - National Drug Observatory (NDO)	Number of NDOs are established and/or strengthened	3 NDOs out of 6 foreseen;		4 to 5 out of 6 NDOs are established and/or strengthened	Fully officially established NDO at national level	NDO existing in their national legislation and operational
	Op 1.2 : updated or new data sets and reports on drug related issues	Number of BC reporting on selected health and security related data sets, using the EMCDDA standard tables (ST)	3 BC out of 6 have reported selected health and security related data through ST		6 BC out of 6 have reported selected health and security related data through ST	Delivery of number of ST	National support / willingness to engage in additional data collection exercises
	Op 1.3: strengthened national Early Warning System (EWS) on new psychoactive substances (NPS)	Number of BC have an established and/or strengthened national EWS on NPS	1 partially functioning EWS		3 to 4 BC have an established and/or strengthened national EWS on NPS	National EWS officially established, incl. active information exchange process	National support / willingness to set up national EWS
	Op 1.4: improved communication and visibility of the project	Number of visibility actions successfully undertaken	<i>n.a.</i>				
	Op 1.5: improved inter-institutional coordination at national and European level	Number of inter-institutional meetings have been organised Number of reports (incl. interim and financial narrative reports) sent to EC	<i>n.a.</i>				

Activities	A.1.1 - Annual update and dissemination of the national roadmaps	<p>Means: A.1.1: Joint updating activity including proofreading, layout and dissemination (EMCDDA and BC). RTX, COM.</p> <p>Costs (for all, EMCDDA and BC human resources): EMCDDA staff (RTX+COM) + BC staff costs</p>
	A.1.2 - Update of the information sources and resources in order to map the flow of drug-related data (Data information maps)	<p>Means: A.1.2: Updating activity following the EMCDDA template (BC), layout and dissemination (annexed to the roadmaps).</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX, COM) + BC staff costs</p>
	A.1.3 - Raising awareness on evidence based policy with national policy makers and Authorities	<p>Means A.1.3.1: High level visits at the EMCDDA, on site visits by the EMCDDA and participation of the BCs' policy makers at selected international conferences (EMCDDA and BC). RTX, EXO, SDI, Director A.1.3.2: training aiming to enhance the national capacity on managerial, media relations, publishing and presentations skills</p> <p>Costs (for all, EMCDDA and BC human resources) A.1.3.1: EMCDDA staff travel + per diems, meeting facility, interpretation</p>
	A.1.4 – Attendance to the annual RTX week	<p>Means A.1.4.1: 2017 and 2018 RTX week</p> <p>Costs (for all, EMCDDA and BC human resources) A.1.4.1: BC staff travel and per diem, meeting facility, interpretation, expert fees, social event</p>
	A 2.1 - Support to data collection and reporting in the drug-related health field	<p>Means A.2.1.1: service contracts for studies (e.g. GPS, ESPAD, web surveys , wastewater) and for setting up national data collection tools (e.g. TDI, DRD); A.2.1.2: ad hoc methodological support by EU experts or EMCDDA staff; A.2.1.3: ad hoc national capacity building activities, A.2.1.4: attendance EMCDDA expert meetings</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA (RTX, ADM, SDI) + BC staff costs EU short-term experts fees + EU short term experts travel and per diem EMCDDA staff travel + per diems BC staff travel and per diems</p>
	A 2.2 - Support to data collection and reporting in the drug-related security field	<p>Means A.2.2.1: service contracts for studies (e.g. drug seizures, prices, purity, DLO) and for setting up national data collection tools (e.g. supply reduction indicators); A.2.2.2: ad hoc methodological support by EU experts or EMCDDA staff; A.2.2.3: ad hoc national capacity building activities, A.2.2.4: attendance EMCDDA expert meetings</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX,ADM, SDI) + BC staff costs EU short-term experts fees + EU short term experts travel and per diem EMCDDA staff travel + per diems BC staff travel and per diems</p>

Activities	A 2.3 - Drafting and publishing of the CDR	<p>Means A.2.3: BC and EMCDDA human resources, service contract for proofreading, layout (RTX, COM, COM, SDI)</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX,ADM, SDI) + BC staff costs</p>
	A.3.1 – Support to capacity to early detect and report on new drugs	<p>Means A.3.1.1: service contracts for setting up national data collection tools; (RTX, ADM) A.3.1.2: ad hoc methodological support by EU experts or EMCDDA staff; (RTX, SAT) A.3.1.3: ad hoc national capacity building activities, (RTX, SAT)</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX, SAT) + BC staff costs EU short-term experts fees + travel and per diem EMCDDA staff travel + per diems BC staff travel and per diems</p>
	A.3.2 - Drafting and publishing of the national EWS profile	<p>Means A.3.2: BC and EMCDDA human resources, service contract for proofreading, layout</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX, SAT, COM) + BC staff costs</p>
	A3.3 – gradual integration of IPA beneficiaries into the European EWS	<p>Means A.3.3: attendance EMCDDA EWS expert meetings (RTX, SDI)</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX, SAT) + BC staff costs EU short-term experts fees + travel and per diem EMCDDA staff travel + per diems BC staff travel and per diems</p>
	A.4.1 - organisation of a launch and close-out events	<p>Means A.4.1.1: 2 meetings</p> <p>Costs (for all, EMCDDA and BC human resources) A.4.1.1: EMCDDA staff travel and per diems, meeting facilities, interpretation</p>
	A.4.2 - organise national visibility event in each of Beneficiary countries	<p>Means A.4.2.1: national meetings</p> <p>Costs (for all, EMCDDA and BC human resources) A.4.1.1: EMCDDA staff travel and per diems, meeting facilities, interpretation</p>
	A.4.3 - Promote project activities and project results in different fora	<p>Means A.4.3.1: attendance CND, EU political dialogue with western Balkans, service contracts for setting up national data collection tools (RTX, ADM staff)</p> <p>Costs (for all, EMCDDA and BC human resources) A.4.3.1: EMCDDA staff travel and per diems</p>
	A.4.4 - Ensure dissemination of the project results and activities via different means	<p>Means A.4.4.4: Project webpage, newsletters, flyers, leaflets</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff costs (RTX + COM)</p>

Activities	A.5.1 - organisation of the annual project steering committee meeting	<p>Means A.5.1.1: Annual meeting</p> <p>Costs (for all, EMCDDA and BC human resources) A.5.1.1: EMCDDA staff travel and per diems, meeting facilities, interpretation</p>
	A.5.2 - organisation of regular meetings with EU services	<p>Means A.5.2.1: Annual meeting A.5.2.2: ad hoc methodological support by EU experts or EMCDDA staff; (RTX, SDI)</p> <p>Costs (for all, EMCDDA and BC human resources) A.5.2.1: EMCDDA staff travel and per diems</p>
	A.5.3 - Organisation of the annual meeting with the NC	<p>Means A. 5.3.1: Annual coordination meeting</p> <p>Costs (for all, EMCDDA and BC human resources) A.5.3.1: EMCDDA staff travel and per diems, meeting facility, interpretation</p>
	A.5.4: Organisation of high level visits at the EMCDDA and on site-visits	<p>Means A. 5.3.1: Internal coordination to organise 1 high-level visit per BC throughout the project</p> <p>Costs (for all, EMCDDA and BC human resources) EMCDDA staff (RTX, DIR, I&L) + BC staff costs Meeting facilities, interpretation BC staff travel and per diems EMCDDA staff travel + per diems, meeting facility, interpretation</p>

Definitions:

“Impact” means the primary and secondary, long term effects produced by the Action.

“Outcome” means the likely or achieved short-term and medium-term effects of an Action’s outputs.

“Output” means the products, capital goods and services which result from an Action’s activities.

“Indicator” is the quantitative and/or qualitative factor or variable that provides a simple and reliable means to measure the achievement of the Results of an Action.

“Baseline” means the starting point or current value of the indicators.

“Target” (or results Goal) means the quantitatively or qualitatively measurable level of expected output, outcome or impact of an Action.

A “logical framework matrix” (or “logframe matrix”) is a matrix in which results, assumptions, indicators, targets, baselines, and sources of verification related to an action are presented.

The intervention logic tells how, in a given context, the activities will lead to the outputs, the outputs to the outcome(s) and the outcome(s) to the expected impact. The most significant assumptions developed in this thinking process are to be included in the logframe matrix.